Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04482894 · ClinicalTrials.gov registry record · Phase 2
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
A Phase 2 study of Myelodysplastic Syndromes and AML, Adult, sponsored by University of Virginia.
- Active
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
- 1
- Study location
NCT04482894: Active Phase 2 study of Myelodysplastic Syndromes and AML, Adult, sponsored by University of Virginia.
NCT04482894 is a Phase 2 study of Myelodysplastic Syndromes and AML, Adult that is active but no longer recruiting, run by University of Virginia. The registered enrollment target is 105 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04482894, a Phase 2 study of Myelodysplastic Syndromes and AML, Adult, is active but no longer recruiting, sponsored by University of Virginia.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.
Primary Outcome
Location of death (ICU, inpatient floor, hospice, home)
Conditions Studied
Interventions
- OTHER Palliative Care Visits
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-08-19 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 2 |
What the registry record for NCT04482894 still lists
NCT04482894 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (63% lower).
The record links to 4 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Palliative Care Visits is the first listed.
NCT04482894 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT04482894 about?
NCT04482894 is a clinical study titled "Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS". The purpose of this study is to estimate the potential benefit of early and continued palliative care (PC) consultation on end of life issues.
What is the current status of trial NCT04482894?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2020-08-19. Estimated completion is 2026-04-01.
What conditions does trial NCT04482894 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, AML, Adult, ALL, Adult, Leukemia, Acute.
What interventions are being tested in trial NCT04482894?
The interventions under investigation include: Palliative Care Visits (OTHER).
Who is sponsoring clinical trial NCT04482894?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04482894 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04482894's enrollment target sits among peer trials
105 53rd of 173 higher than 121 of 173 other Myelodysplastic Syndromes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndromes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
RECRUITING · Phase 2
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Ascorbate in Myelodysplastic Syndrome
RECRUITING · Phase 2
-
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI